Cambridge Cognition Holdings PLC Contract Win (6495E)
July 20 2016 - 2:00AM
UK Regulatory
TIDMCOG
RNS Number : 6495E
Cambridge Cognition Holdings PLC
20 July 2016
20 July 2016
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
GBP0.5m contract win for Research business
The neuroscience company Cambridge Cognition Holdings PLC
(Cambridge, UK - LSE: COG), which develops and markets near patient
technologies for cognitive assessment, today announced that it has
secured its largest contract to date for the CANTAB Connect
Research(R) product, which is marketed for use in research projects
by academic and small biotechnology research groups ("the
Contract").
Worth an estimated GBP0.5 million, the Contract is the Company's
first with an international biobank and the highest recorded sale
of its research software. Biobanks amass large amounts of data and
biological samples and catalogue them according to genetic,
biological, environmental and other traits. These data and samples
are then made available for researchers to support medical research
in many fields. There are over 300 biobanks globally and the
addition of neurological health data generated using Cambridge
Cognition products will help to progress research into prevalent
health issues, now and in the future.
The Contract allows for unlimited assessments to be conducted
using the Company's proprietary touchscreen cognitive tests based
on over 30 years of peer-reviewed science. The software will
generate data that will be used for medical research to assess
mental health in a general population over the next five years.
Dr Steven Powell, Chief Executive Officer, Cambridge Cognition:
"Biobanks play a crucial role in biomedical research, enabling
pharmaceutical companies to translate research into better
treatments. We are therefore excited to be working in partnership
with biobanks internationally, helping them advance drug
development by enhancing their research capabilities."
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
Enquiries
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Tel: 01223 810
Officer 700
Noah Konig, Director of Product press@camcog.com
Marketing and Communications
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane (Corporate Broking)
Hybridan LLP (Joint Broker) Tel: 020 3764
2341
Claire Noyce (Corporate Broking)
Notes to editors
About Cambridge Cognition
Cambridge Cognition is an international neuroscience company
which develops and markets near patient cognitive assessment
products to improve the understanding, diagnosis and treatment of
neurological and psychiatric disorders.
For over 30 years the company's patented technology has advanced
the assessment of cognition to accelerate the development of safe
and effective treatments, improve patient outcomes and monitor and
manage cognitive health throughout life.
Partners include the world's leading biotechnology and
pharmaceutical companies; leading academic institutions; and
public-private healthcare providers.
www.cambridgecognition.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTUKSVRNRABAAR
(END) Dow Jones Newswires
July 20, 2016 02:00 ET (06:00 GMT)